Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Neoplasms
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
This is a late phase II, prospective, multicenter randomized study, to assess the value of early palliative care integrated with the standard oncologic care in patients with Recurrent Metastatic (RM) Head and Neck Cancer (HNC)…
- Trial name
- SupCare (NCT06347185)
- Testing
- Early palliative care, integrated with the standard oncologic care (proactive approach), Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent High Grade Meningioma
Trabectedin for Recurrent Grade II/III Meningioma
The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.
- Trial name
- NCT02234050
- Testing
- Trabectedin, Local standard of care
- Where
- 47 sites in Austria, Belgium and 8 more
- Volunteers
- 90 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Newly Diagnosed Glioblastoma
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal.
- Trial name
- MIRAGE (NCT03345095)
- Testing
- Marizomib, Temozolomide, radiotherapy
- Where
- 82 sites in United States, Austria and 10 more
- Volunteers
- 749 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
GastroEsophageal Cancer
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
This is an open-label,multi-centre, phase 1b safety and feasibility study aiming to assess the safey and feasibility of bemarituzumab plus chemiotherapy (FLOT) for the peri-operative treatment of resectable gastroesophageal…
- Trial name
- NeoBEMA (NCT06978062)
- Testing
- Bemarituzumab, FLOT
- Volunteers
- 27 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colon Cancer
Adjuvant Aspirin Treatment for Colon Cancer Patients
Following complete resection of their primary tumor, potentially eligible stage II or stage III colon cancer patients will undergo central PIK3CA testing.
- Trial name
- NCT02467582
- Testing
- Aspirin
- Where
- 60 sites in Belgium, Germany and 2 more
- Volunteers
- 1,040 people
- Sponsor
- Swiss Cancer Institute
Cancer
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach.
- Trial name
- E²-RADIatE (NCT03818503)
- Where
- 77 sites in Austria, Belgium and 12 more
- Volunteers
- 2,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastric Cancer
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Gastric cancer remains a significant global public health problem. Although in developed countries its incidence has dramatically decreased, on a worldwide scale it is still a leading cause of cancer-related deaths.
- Trial name
- TOPGEAR (NCT01924819)
- Testing
- Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel, Preoperative chemoradiotherapy, Gastric resection
- Where
- 59 sites in Australia, Belgium and 8 more
- Volunteers
- 574 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Metastatic Prostate Cancer
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
This is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient…
- Trial name
- PEACE1 (NCT01957436)
- Testing
- abiraterone acetate, radiotherapy, Androgen Deprivation Therapy
- Where
- 77 sites in Belgium, France and 5 more
- Volunteers
- 1,173 people
- Sponsor
- UNICANCER
Salivary Gland Cancer
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers.
- Trial name
- NCT01969578
- Testing
- bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 149 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Small Cell Lung Cancer
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
This study includes patients diagnosed with a metastatic non small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) translocation.
- Trial name
- ALKALINE (NCT04127110)
- Testing
- Lorlatinib
- Where
- 26 sites in Belgium, France and 5 more
- Volunteers
- 68 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
ER+ Breast Cancer, HER2-negative Breast Cancer
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer
This study is a pragmatic international, multicenter, randomized, open label 3- arm trial of standard care vs. two pharmacological interventions: duloxetine or furosemide in patients with stage I-III ER+/HER2- early breast cancer…
- Conditions
- ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II
- Trial name
- NCT06407401
- Testing
- Duloxetine 60 MG, Furosemide 40 mg, Booklet for healthy behaviors
- Volunteers
- 399 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gynecologic Cancer, Skin Cancer
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
- Conditions
- Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- OligoRARE (NCT04498767)
- Testing
- Stereotactic body radiotherapy, Palliative RT
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, Survivorship
Validation of the European Oncology Quality of Life Toolkit
The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship…
- Conditions
- Cancer, Survivorship, Palliative Care
- Trial name
- NCT05947903
- Testing
- Administration of the EUonQoL-Kit - Active Treatment questionnaire, Administration of the EUonQoL-Kit - Survivors questionnaire, Administration of the EUonQoL-Kit - Palliative Care questionnaire
- Where
- 45 sites in Albania, Austria and 30 more
- Volunteers
- 4,000 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Bladder Cancer
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
The investigators aim to investigate a possible role for radiotherapy in good prognosis bladder cancer patients has been identified as a possible alternative to cystectomy, especially for patients non-eligible for surgery but has…
- Trial name
- NCT06310369
- Testing
- radiation therapy
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oral Cavity Squamous Cell Carcinoma
Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity
This is a randomized, open-label, prospective, pilot phase I/II study with focus on translational research and on the evaluation of the biological changes that are observed in sequential tumor tissue acquisition in patients with…
- Trial name
- DUTRELASCO (NCT03784066)
- Testing
- Durvalumab, Durvalumab + Tremelimumab
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Quality of Life, Adverse Effects
International Validation of the QLQ-OH17 for Oral Health
Assessment of oral and dental problems is seldom routine in clinical oncology, despite the potential negative impact of these problems on nutritional status, social function and quality of life (QoL).
- Conditions
- Quality of Life, Adverse Effects, Late Effects, Cancer
- Trial name
- QLQ-OH17 (NCT01724333)
- Where
- 14 sites in France, Germany and 8 more
- Volunteers
- 585 people
- Sponsor
- Oslo University Hospital
Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device (DaRT) as a treatment prior to additional radiation or chemo therapy.
- Trial name
- NCT05065346
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT
- Where
- Israel
- Volunteers
- 79 people
- Sponsor
- Alpha Tau Medical LTD.
Stage IB-IIB Cutaneous T-Cell Lymphoma
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma (CTCL) has a chronic, relapsing course with patients undergoing multiple, consecutive therapies. Treatment aims at the clearance of skin disease, minimization of recurrence, prevention of disease…
- Trial name
- MOGAT (NCT04128072)
- Testing
- Mogamulizumab, Total Skin Electron Beam Therapy (TSEB), Mogamulizumab (subsequent cycles post TSEB)
- Where
- 13 sites in Denmark, France and 5 more
- Volunteers
- 43 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00036868
- Testing
- trastuzumab, CMF regimen, cyclophosphamide
- Where
- 13 sites in Belgium, Denmark and 7 more
- Volunteers
- 90 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- LAPATAM (NCT00424164)
- Testing
- lapatinib ditosylate, tamoxifen citrate, pharmacological study
- Where
- France
- Volunteers
- 20 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC